First-Line Atezolizumab Effective in Cisplatin-Ineligible Urothelial Cancer
Results of the IMvigor210 clinical trial found that atezolizumab is effective in patients with locally advanced or metastatic cisplatin-ineligible urothelial carcinoma.
Results of the phase II IMvigor210 clinical trial found that atezolizumab, a PD-L1 inhibitor, produced an overall response rate of 24% in patients with locally advanced or metastatic cisplatin-ineligible urothelial carcinoma. The study (abstract LBA4500) reported a median overall survival rate of 14.8 months, regardless of PD-L1 expression.
The data were presented by Arjun V. Balar, MD, of the NYU Perlmutter Cancer Center in New York, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3–7 in Chicago. In this video Dr. Balar discusses the results.
